Search Results for “Clinical Trial” – Page 92 – media

Alnylam Presents Promising Results for RNAi Therapeutic in Alzheimer’s Disease at AAIC

Alnylam Pharmaceuticals’ investigational RNAi therapeutic has shown promise in patients with early-onset Alzheimer’s disease, according to phase 1 results presented by the company at this year’s Alzheimer’s Association International Conference (AAIC). Interim results from the early-stage study showed that a single injection of ALN-APP, which is designed to switch off the production of amyloid precursor protein (APP) in the central nervous system, was able to rapidly reduce levels of the protein, with clinical effect sustained over six months. ALN-APP is being developed in collaboration with Regeneron Pharmaceuticals for both Alzheimer’s disease and the related disorder cerebral amyloid angiopathy (CAA) and is now the first investigational RNAi therapeutic to demonstrate gene silencing in the human brain. “We’ve known for decades that mutations that increase APP production, or alter its proteolysis, cause early-onset Alzheimer’s disease, early-onset CAA or both,” said Dr Sharon Cohen, neurologist and medical director, Toronto ...
- Source: drugdu
- 117
- July 20, 2023
Black Patients with ICDs Have Higher Rate of Post-Implant Cardiac Events and Risk of Death

Black patients with implantable cardioverter defibrillators (ICDs) have a significantly higher burden of disease than white patients with the same device, according to a new study from University of Rochester Medical Center (URMC) cardiology researchers. Analyzing data from clinical trials conducted over a 20-year period by the Clinical Cardiovascular Research Center (CCRC) at URMC, investigators concluded that not only did Black patients with ICDs tend to be significantly younger than white patients, but they also had a higher rate of post-implant cardiac events and risk of death. When a patient is at risk for cardiac arrest, an ICD helps to monitor their heart rhythm, and if an abnormality is detected, the device delivers a shock of electricity to reset the heartbeat to a normal rhythm. The study, published in Circulation, examines the rate of events that a patient experiences after their ICD is implanted. After three years of ...
- Source: drugdu
- 125
- July 19, 2023
Portable, Low-Cost Tech Tracks Uterine Contractions

Chakrabartty’s lab created a battery-powered portable instrumentation that connects with a stretchy patch that places electrodes around the wearer’s abdomen. The electrodes detect both maternal heartbeat and EMG signals, which correspond to uterine contractions. Chuan Wang created flexible electrodes that Chakrabartty’s group used to build the device. Credit: Washington University in St. Louis Keeping track of pregnancy requires a dizzying array of gargantuan and expensive machines. An MRI machine is the size of a room and can cost up to $1 million. But the care such equipment provides is a critical part of prenatal care, especially for dealing with complications like preterm birth. To get this care, pregnant people frequently need to visit a hospital, a significant burden for underserved and disadvantaged communities. In a paper published May 19 in early access online in IEEE Transactions on Biomedical Circuits and Systems, a collaboration of researchers at Washington University St. ...
- Source: drugdu
- 99
- July 19, 2023
Urotronic Wins FDA Approval to challenge Boston Scientific, Teleflex for Prostate Market

Dive Brief The U.S. Food and Drug Administration has approved Urotronic’s minimally invasive surgical treatment of symptoms linked to benign prostatic hyperplasia (BPH), the company announced Tuesday. BPH is defined by the expansion of the prostate. As the organ grows, it can cause changes in the bladder that result in lower urinary tract symptoms such as leaking urine. Urotronic’s newly approved Optilume BPH catheter system is designed to tackle the symptoms through mechanical dilation and the delivery of paclitaxel to stop the problem from recurring. Dive Insight Researchers studied the use of balloon dilation in BPH in the 1990s, but the technique failed to provide long-term benefits. Urotronic has tried to address that problem by pairing the immediate symptomatic relief provided by balloon dilation with localized delivery of paclitaxel, a drug that is already widely used in cardiovascular devices to prevent blood vessels from narrowing after ...
- Source: drugdu
- 118
- July 15, 2023
Can CorWave Fill Medtronic’s Shoes in the LVAD Market?

Medtronic’s exit from the left ventricular assist device (LVAD) market left a huge void. A small French company wants to fill it. A small French company has some mighty big shoes to fill in the left ventricular assist device (LVAD) market. When Medtronic pulled the plug on its embattled HeartWare ventricular assist device in 2021, the departure created a significant void in the LVAD market and highlighted the urgent need for innovation in the space to improve outcomes for end-stage heart failure patients. Abbott said it had the capacity and supply to effectively support the growing demand for mechanical circulatory support devices with its HeartMate 3 device, but Abbott and other LVAD makers suffer from limitations of using rotary pump technology, according to CorWave CEO Louis de Lillers. Clichy, France-based CorWave is developing an implantable heart pump for advanced heart failure patients that is based on a technology called ...
- Source: drugdu
- 97
- July 15, 2023
NVIDIA Doubles Down on AI Drug Discovery with $50M Recursion Investment

Clinical-stage biotech Recursion continues to go from strength to strength. After its recent acquisition of Cyclica and Valence, the company announced a partnership with—and $50 million investment from—NVIDIA on Wednesday. Under the agreement, the tech giant is giving Recursion a $50 million private investment in public equity. The two companies are looking to accelerate the development of Recursion’s AI foundation models to help the biopharma industry create improved patient therapies more quickly. “With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space,” Recursion CEO Chris Gibson said in a statement. Recursion has built a massive biological and chemical database via its Recursion OS, which exceeds 23 petabytes and has three trillion searchable compound and gene relationships. The company has been training machine-learning algorithms on this dataset to tackle the complex ...
- Source: drugdu
- 122
- July 14, 2023
BeiGene Signs $1.3bn Deal with DualityBio for Investigational Solid Tumour ADC

BeiGene has acquired an exclusive option for a global licence to one of DualityBio’s investigational, preclinical antibody-drug conjugates (ADC) for solid tumours. Though few details of the agreement were disclosed, it has been confirmed that DualityBio will receive undisclosed upfront payments from BeiGene and will be eligible to receive certain development, regulatory, and commercial milestone payments totalling up to $1.3bn. ADCs are a class of cancer therapies that combine the selectivity of antibodies with the potent cell-killing properties of chemotherapy or other anti-cancer agents. Unlike chemotherapy, which works by attacking lots of different cells as well as the cancer, ADCs are designed to target and kill tumour cells while sparing healthy cells. BeiGene’s global head of research and development, Lai Wang, said: “Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our ...
- Source: drugdu
- 123
- July 14, 2023
Anti-inflammatory Drugs Do Not Lead to a Swifter Hospital Exit

Anti-inflammatory drugs may reduce deaths due to Covid-19, but they do not help speed up the recovery for those in hospital, according to a recent study. Results from s study, published in The Journal of the American Medical Association, demonstrated that giving abatacept, cenicriviroc, or Johnson and Johnson’s Remicade (infliximab) in addition to standard of care did not decrease time to recovery for patients hospitalised with Covid-19 pneumonia. The standard of care included in this study involved Gilead Sciences’ Veklury (remdesivir) and the corticosteroid dexamethasone. Patients who took either one of the three drugs recovered after a similar number of days compared to those who were on placebo. The investigators also measured mortality across the sub-studies by day 28 – which did show slight differences, though not statistically significant. Abatacept and Remicade led to a narrow decrease in patient deaths – a 4.1% and 4.4% difference respectively, whilst ...
- Source: drugdu
- 132
- July 13, 2023
UAE, Saudi Arabia Serve as Gateway to International Markets for Biopharma

Biopharma companies, including Sanofi, AbbVie and Virax Biolabs, are finding significant business opportunities in the Middle East, particularly in the United Arab Emirates and Saudi Arabia. These countries have emerged as attractive markets for novel therapies, driven by growing populations with increasing incidences of chronic diseases such as diabetes and cardiovascular diseases. The Middle East is emerging as a key healthcare market, with an increasing demand for innovative healthcare solutions, particularly after the region struggled to meet the challenges brought on by the pandemic, said Cameron Shaw, chief operating officer for Virax Biolabs, which recently made a deal to set up a regional headquarters in the Dubai Science Park in the UAE. “The UAE was hit very hard by the COVID pandemic, similarly to how everyone in the world was affected,” Shaw told BioSpace. This is partly due to the high prevalence of diabetes and obesity in Dubai and Saudi Arabia, he ...
- Source: drugdu
- 147
- July 13, 2023
CMS Expands Medicare Coverage for Leqembi After FDA Traditional Approval

Pictured: Sign of U.S. Department of Health & Human Services at its headquarters in Washington/iStock, JHVEPhoto The Centers for Medicare and Medicaid Services will now provide broader coverage for Eisai and Biogen’s Alzheimer’s disease therapy Leqembi (lecanemab), the federal agency announced Thursday. The Medicare coverage expansion comes after Leqembi won the FDA’s traditional approval, making it the first anti-amyloid and disease-altering treatment to do so. Eisai and Biogen were granted accelerated approval for Leqembi in January and soon commenced their bid for full approval with data from the Phase III Clarity-AD study. According to CMS, only patients enrolled in Medicare and with physicians participating in a qualified registry will be eligible for reimbursement—provided their doctors collect their data as real-world evidence for Leqembi and submit it to a registry. Coverage is restricted to those who are diagnosed with mild cognitive impairment or mild Alzheimer’s disease dementia, with evidence of beta-amyloid deposits in the brain. “With FDA’s decision, CMS will ...
- Source: drugdu
- 128
- July 11, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.